https://adisinsight.springer.com/drugsafety/803820990?error=cookies_not_supported&code=a09a8def-021d-47cf-87b7-9e44398c1b1e
Catequentinib/pembrolizumab - AdisInsight
A 54-year-old woman developed hepatitis, liver cirrhosis and hypothyroidism during treatment with pembrolizumab for pulmonary lymphoepithelioma-like carcinoma
pembrolizumabadisinsight
https://adisinsight.springer.com/drugsafety/803924060?error=cookies_not_supported&code=61f411d2-a5c2-415c-bb2c-231dc5bfdf72
Catequentinib/Tipiracil/trifluridine - AdisInsight
Twenty-one patients with metastatic colorectal cancer, median age 62 years [*sex not stated for individual cases*], received oral anlotinib and
adisinsight
https://adisinsight.springer.com/drugsafety/803893377?error=cookies_not_supported&code=6dd18c88-f2b4-4b5d-8aa2-5e0133ecb2f8
Catequentinib - AdisInsight
A single-centre, retrospective study of 45 patients was conducted between June 2018 and August 2021, 2 patients [ages and sexes not stated] were described, who
adisinsight
https://adisinsight.springer.com/drugsafety/803927096?error=cookies_not_supported&code=e8f373fa-3dc2-44aa-9c76-c615fc00c049
Pembrolizumab/Catequentinib - AdisInsight
A report described 41 patients with advanced oral mucosal melanoma, whose ages and sexes were [not stated], who received pembrolizumab with anlotinib [doses,
pembrolizumabadisinsight
https://adisinsight.springer.com/drugsafety/803861815?error=cookies_not_supported&code=f22d13b3-2b44-4197-bb2e-83a04a5c1b09
Camrelizumab/catequentinib - AdisInsight
In a retrospective study of 68 patients with metastatic colorectal cancer (CRC), who enrolled between August 2018 and December 2022, a woman [age not stated]
adisinsight
https://adisinsight.springer.com/drugsafety/803845796?error=cookies_not_supported&code=16245a9d-85f7-4367-b8c9-e7f1a4f75eea
Catequentinib/nivolumab - AdisInsight
A man in his 70s [exact age not stated] developed progressive maculopapular rash and pruritus during treatment with nivolumab for stage 3 C metastatic lung
nivolumabadisinsight
https://adisinsight.springer.com/drugsafety/803824372?error=cookies_not_supported&code=0a528394-5727-46dc-bad0-980d4a215065
Catequentinib/nivolumab - AdisInsight
A 61-year-old man exhibited a lack of efficacy following treatment with catequentinib and nivolumab for diffuse malignant peritoneal mesothelioma (DMPM) [not
nivolumabadisinsight
https://adisinsight.springer.com/drugsafety/803895797?error=cookies_not_supported&code=2fe85c26-b1be-45d5-b615-4af8cf142d8f
Catequentinib - AdisInsight
A 42-year-old woman developed hypertension and hand-foot syndrome following off-label treatment with catequentinib for stage IB2 metastatic squamous cell
adisinsight
https://adisinsight.springer.com/drugsafety/803871116?error=cookies_not_supported&code=ce7ebe1d-7650-477f-bc3c-729ecf1dd76b
Antibacterials/catequentinib/tislelizumab - AdisInsight
A woman in her 70's [exact age not stated] exhibited lack of efficacy during treatment with piperacillin/tazobactam and doxycycline for pneumonia. Additionally,
antibacterialsadisinsight